Attached files
file | filename |
---|---|
EX-99.1 - EX-99.1 - Tempest Therapeutics, Inc. | a15-20341_1ex99d1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): September 28, 2015
OvaScience, Inc.
(Exact name of registrant as specified in its charter)
Delaware |
|
001-35890 |
|
45-1472564 |
(State or other jurisdiction |
|
(Commission |
|
(IRS Employer |
215 First Street, Suite 240 |
|
02142 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrants telephone number, including area code: (617) 500-2802
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 8.01 Other Events.
On September 28, 2015, OvaScience, Inc. issued a press release announcing an update of its corporate goals for the AUGMENTSM Treatment. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
ITEM 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibits Number |
|
Description |
|
|
|
99.1 |
|
Press Release, dated September 28, 2015 |